Simulations Plus Chief Science Officer Dr. Viera Lukacova Honored as Fellow by the American Association of Pharmaceutical Scientists (AAPS)
August 24 2023 - 8:30AM
Business Wire
Dr. Lukacova’s outstanding contributions to
pharmaceutical research and innovation to be recognized with seven
others at AAPS PharmSci 360
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of
modeling and simulation solutions for the pharmaceutical and
biotechnology industries, is proud to announce that Dr. Viera
Lukacova, Chief Science Officer of the SLP Division, has been
elevated to the status of Fellow within the American Association of
Pharmaceutical Scientists (AAPS) and will be formally inducted at
the annual PharmSci 360 meeting on October 22, 2023.
“Viera stands out as an eminent figure whose profound
contributions have significantly shaped the landscape of
physiologically based pharmacokinetics (PBPK) modeling,” said John
DiBella, President of the SLP Division at Simulations Plus. “Her
scientific insights have advanced the capabilities of software
platforms like GastroPlus®, DDDPlus™, and MembranePlus™ that
scientists use every day to develop safe and effective treatments
for patients worldwide. A tireless advocate, her impact also
extends beyond research into the realms of publication,
presentation, and education. Through her visionary leadership,
pioneering research, and relentless dedication, she has elevated
PBPK modeling to unprecedented heights, and we cannot wait to
celebrate the well-deserved status she has achieved within AAPS at
October’s meeting.”
“The Class of 2023 AAPS Fellows […] were selected based on
well-defined criteria for outstanding scientific accomplishments,
significant and sustained impact in the pharmaceutical sciences,
and exceptional service to the AAPS community,” said AAPS 2023
Fellows Committee Chair Mandip Singh Sachdeva, Ph.D., FAAPS.
Joining Dr. Lukacova as 2023 AAPS Fellows are Dr. Shaukat Ali,
Dr. Ben Boyd, Dr. Maria Croyle, Dr. Otilia Koo, Dr. Xiuling Lu, Dr.
Wellington Pham, and Dr. Patrick Ronaldson.
To meet with Dr. Lukacova at the 2023 AAPS PharmSci 360 meeting
in Orlando, Florida, and learn more about her work, we invite you
to schedule a meeting and visit Simulations Plus at booth #2301 in
the exhibit hall.
About Simulations Plus
Serving clients worldwide for more than 25 years, Simulations
Plus is a leading provider in the biosimulation market providing
software and consulting services supporting drug discovery,
development, research, and regulatory submissions. We offer
solutions that bridge artificial intelligence (AI)/machine
learning, physiologically based pharmacokinetics, quantitative
systems pharmacology/toxicology, and population PK/PD modeling
approaches. Our technology is licensed and applied by major
pharmaceutical, biotechnology, and regulatory agencies worldwide.
For more information, visit our website at
www.simulations-plus.com. Follow us on LinkedIn | Twitter |
YouTube.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts
where we can have the most positive impact. To learn more about our
latest initiatives and priorities, please visit our website to read
our 2022 ESG update.
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995 – With the exception of historical
information, the matters discussed in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Words like “believe,” “expect” and “anticipate” mean
that these are our best estimates as of this writing, but that
there can be no assurances that expected or anticipated results or
events will actually take place, so our actual future results could
differ significantly from those statements. Factors that could
cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the
pharmaceutical industry, our ability to finance growth, our ability
to continue to attract and retain highly qualified technical staff,
our ability to identify and close acquisitions on terms favorable
to the Company, and a sustainable market. Further information on
our risk factors is contained in our quarterly and annual reports
and filed with the U.S. Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230824191955/en/
Simulations Plus Investor Relations
Renee Bouche 661-723-7723 renee.bouche@simulations-plus.com
Financial Profiles Tamara Gonzalez
310-622-8234 slp@finprofiles.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Jul 2023 to Jul 2024